Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

被引:539
作者
Dubuc, G
Chamberland, A
Wassef, H
Davignon, J
Seidah, NG
Bernier, L
Prat, A
机构
[1] Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada
[2] Clin Res Inst Montreal, Lab Hyperlipidemia, Montreal, PQ H2W 1R7, Canada
[3] Clin Res Inst Montreal, Atherosclerosis Res Grp, Montreal, PQ H2W 1R7, Canada
关键词
cholesterol; QPCR; SRE; HepG2; primary hepatocytes;
D O I
10.1161/01.ATV.0000134621.14315.43
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-Neural apoptosis-regulated convertase (NARC)-1 is the newest member of the proprotein convertase family implicated in the cleavage of a variety of protein precursors. The NARC-1 gene, PCSK9, has been identified recently as the third locus implicated in autosomal dominant hypercholesterolemia (ADH). The 2 other known genes implicated in ADH encode the low-density lipoprotein receptor and apolipoprotein B. As an approach toward the elucidation of the physiological role(s) of NARC-1, we studied its transcriptional regulation. Methods and Results-Using quantitative RT-PCR, we assessed NARC-1 regulation under conditions known to regulate genes involved in cholesterol metabolism in HepG2 cells and in human primary hepatocytes. We found that NARC-1 expression was strongly induced by statins in a dose-dependent manner and that this induction was efficiently reversed by mevalonate. NARC-1 mRNA level was increased by cholesterol depletion but insensitive to liver X receptor activation. Human, mouse, and rat PCSK9 promoters contain 2 typical conserved motifs for cholesterol regulation: a sterol regulatory element (SRE) and an Sp1 site. Conclusions-PCSK9 regulation is typical of that of the genes implicated in lipoprotein metabolism. In vivo, PCSK9 is probably a target of SRE-binding protein (SREBP)-2.
引用
收藏
页码:1454 / 1459
页数:6
相关论文
共 39 条
[1]   Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].
Abifadel, M ;
Varret, M ;
Rabès, JP ;
Allard, D ;
Ouguerram, K ;
Devillers, M ;
Cruaud, C ;
Benjannet, S ;
Wickham, L ;
Erlich, D ;
Derré, A ;
Villéger, L ;
Farnier, M ;
Beucler, I ;
Bruckert, E ;
Chambaz, J ;
Chanu, B ;
Lecerf, JM ;
Luc, G ;
Moulin, P ;
Weissenbach, J ;
Prat, A ;
Krempf, M ;
Junien, C ;
Seidah, NG ;
Boileau, C .
NATURE GENETICS, 2003, 34 (02) :154-156
[2]   Transcriptional activities of nuclear SREBP-1a,-1c, and-2 to different target promoters of lipogenic and cholesterogenic genes [J].
Amemiya-Kudo, M ;
Shimano, H ;
Hasty, AH ;
Yahagi, N ;
Yoshikawa, T ;
Matsuzaka, T ;
Okazaki, H ;
Tamura, Y ;
Iizuka, Y ;
Ohashi, K ;
Osuga, J ;
Harada, K ;
Gotoda, T ;
Sato, R ;
Kimura, S ;
Ishibashi, S ;
Yamada, N .
JOURNAL OF LIPID RESEARCH, 2002, 43 (08) :1220-1235
[3]  
BRIGGS MR, 1993, J BIOL CHEM, V268, P14490
[4]   Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects [J].
Cohn, JS ;
Tremblay, M ;
Amiot, M ;
Bouthillier, D ;
Roy, M ;
Genest, J ;
Davignon, J .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (01) :149-159
[5]   Low-density lipoprotein-independent effects of statins [J].
Davignon, J ;
Laaksonen, R .
CURRENT OPINION IN LIPIDOLOGY, 1999, 10 (06) :543-559
[6]   The cardioprotective effects of statins [J].
Davignon J. .
Current Atherosclerosis Reports, 2004, 6 (1) :27-35
[7]  
DEHOFF JL, 1978, CLIN CHEM, V24, P433
[8]   Expression, regulation, and activity of ABCA1 in human cell lines [J].
Denis, M ;
Bissonnette, R ;
Haidar, B ;
Krimbou, L ;
Bouvier, M ;
Genest, J .
MOLECULAR GENETICS AND METABOLISM, 2003, 78 (04) :265-274
[9]   ML-236A, ML-236B, AND ML-236C, NEW INHIBITORS OF CHOLESTEROGENESIS PRODUCED BY PENICILLIUM CITRINUM [J].
ENDO, A ;
KURODA, M ;
TSUJITA, Y .
JOURNAL OF ANTIBIOTICS, 1976, 29 (12) :1346-1348
[10]  
GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241